Search Medical Condition
Please enter condition
Please choose location from dropdown
 

Nurmijarvi, Finland Clinical Trials

A listing of Nurmijarvi, Finland clinical trials actively recruiting patients volunteers.

RESULTS

Found (5) clinical trials

A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age.

This study is examining safety and immunogenicity of 2 doses of Trumenba administered on a 0-,6- month schedule. This trial is also studyng safety and immunogenicity of a meningococcal pentavalent vaccine.

Phase

9.13 miles

Learn More »

Immunogenicity and Safety of a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine in Children

Healthy children who were vaccinated 3 years earlier at 12 to 23 months of age in study MET54 (NCT03205358) are eligible for enrollment. All participants will receive a single booster dose of MenACYW conjugate vaccine on Day 0. Immunogenicity will be assessed pre-vaccination and 30 to 44 days after vaccination. ...

Phase

9.13 miles

Learn More »

A Study to Evaluate the Safety Tolerability and Immunogenicity of an Investigational RSV Vaccine Candidate (Ad26.RSV.preF) in Adults 18 to 50 Years of Age and RSV-seropositive Toddlers 12 to 24 Months of Age

The study, designed to assess the safety and tolerability of two doses given one month apart of Ad26.RSV.preF, an investigational RSV vaccine candidate based on a Ad26 vector expressing the RSV F protein, will be conducted in a double blinded manner. The study will be divided in two sequential cohorts: ...

Phase

9.13 miles

Learn More »

Efficacy Safety and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Adults

This randomized, observer-blind, placebo-controlled multicenter, Phase 3 study will be conducted at multiple sites. The composition of the Quadrivalent VLP Influenza Vaccine to be used in this study includes a mix of recombinant H1, H3, and two B hemagglutinin proteins expressed as VLPs for the 2017-2018 influenza virus strains. Approximately ...

Phase

9.89 miles

Learn More »

Immunogenicity and Safety of Sci-B-Vac to Engerix-B in Adults 18 Years Old and Superiority in Adults 45 Years Old.

This study is a double-blind randomized controlled trial designed to establish the non-inferiority of Sci-B-Vac compared to Engerix-B in adults 18 years old and the superiority of Sci-B-Vac compared to Engerix-B in adults 45 years old. Study subjects will be randomized 1:1 to receive either a total of 3 injections ...

Phase

9.89 miles

Learn More »